Glimy M 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or on monotherapy with either agent. Glimy M 2 Tablet PR is designed for prolonged release, ensuring a steady plasma concentration, which may reduce dosing frequency and improve patient compliance. It is essential to initiate therapy alongside lifestyle modifications such as diet and exercise. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. Common adverse effects include gastrointestinal disturbances, hypoglycemia, and rarely lactic acidosis. This medication should be used under medical supervision, with dose adjustments based on therapeutic response and tolerability. Glimy M 2 Tablet PR offers an effective dual mechanism approach to glycemic control in type 2 diabetes management.